Smith & Nephew plc vs Vanguard Ultra Short Bond ETF — how do they compare? Smith & Nephew plc trades at $27.96 (market cap $11.62B), while Vanguard Ultra Short Bond ETF trades at $47.55. The key difference: Smith & Nephew plc pays a 2.86% dividend while Vanguard Ultra Short Bond ETF pays none, and Smith & Nephew plc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNN | VUSB | |
|---|---|---|
Market Cap | $11.62B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $38.53 | $50.03 |
52-Week Low | $27.80 | $49.55 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.86% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
VUSB trades at $49.595 with minimal daily movement, showing a slight decline of 0.01%. The technical picture is bearish with moving averages signaling selling pressure, though oscillators suggest potential short-term recovery. Recent dividend distributions of $0.17-0.18 per share demonstrate consistent income generation. Market sentiment is influenced by Federal Reserve interest rate expectations favoring short-term bonds.
The outlook remains cautious with bearish technical indicators offset by positive sentiment around short-term bond strategies. Investment opportunity lies in the ETF's defensive positioning amid potential rate hikes, while risks include interest rate sensitivity and market volatility. The stock presents a conservative income play in uncertain monetary policy environments.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →